Models of tauopathy
US12391920B2 · kind B2 · utility
0Cited by
7References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2024 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | Aug 29, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.